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Abstract
Background: Although female sex workers (FSWs) are a well-known high-risk group for Human Papillomavirus
(HPV) infections, few tailored intervention programmes for HPV have been established worldwide. The lack of
reliable data on the prevalence of HPV and related cervical lesions hampers the establishment of evidence-based
intervention programmes.
The objectives of this study were to describe the prevalence of high-risk Human Papillomavirus (hrHPV) infections
and abnormal pap smears in FSWs compared to a control group in Antwerp, Belgium.
Methods: HPV genotyping and cytology data were analysed from routine Pap smear tests that were collected from
both FSWs and the general population (1334 samples for each group) between June 2006 and June 2010. Within
the laboratory database, all FSWs were matched 1:1 for age and testing date to determine the ORs of hrHPV
genotypes, DNA and cytology outcome.
Results: The prevalence of hrHPV DNA in FSWs was 41.7 % compared to 19.8 % in the age-matched controls with
an overall OR of 2.8 (95 % CI: 2.3–3.4). Significant differences were observed in all age groups, and the most
significant differences were observed in the cohort under 21 years of age (prevalence of 64.4 % in FSWs versus 14.
8 % in controls; OR 10.3 (95 % CI: 5.0–21.2). Significantly more cervical lesions were observed in FSWs, particularly in
the 17- to 21-year old age group (OR for LSIL or HSIL: 10.3 (95 % CI: 3.2–33.8). In both groups, HPV 16 was the most
prevalent at 12.1 and 6.6 % in the FSW and control groups, respectively. HPV 18 was the 8th and 7th most frequent
genotype at 5.0 and 2.5 % in the FSW and control groups, respectively.
Conclusions: FSWs have a significantly higher prevalence of hrHPV and more abnormal Pap smears than does the
general population in Antwerp, Belgium. The hrHPV prevalence in FSWs is similar to that reported in the literature.
The need for tailored intervention programmes should be investigated further.
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Background
Worldwide, cervical cancer is the fourth most frequent
type of cancer in women and causes an estimated 270,000
deaths every year [1]. High-risk Human Papillomavirus
(hrHPV) infections are encountered in 90–100 % of all
cervical tumours [2–4]. However, over 70 % of hrHPV
infections are transient [5]. Worldwide, the overall
prevalence of HPV for women with normal cytology is
10 % [6, 7].
In Belgium, the most common hrHPV genotypes are
type 16 (3.7 %), 31 (3.0 %), 51 (2.3 %), 53 (2.1 %) and 59
(1.7 %), followed by HPV type 18 (1.5 %) [8]. In general,
well-known cofactors for HPV infection include low so-
cioeconomic status, long-term use of oral contraception,
sexually promiscuous behaviour, smoking, HSV-2 sero-
positivity, and high parity [9].
Although female sex workers (FSWs) are a well-
known high-risk group for HPV infections, few tailored
intervention programmes for HPV have been established
worldwide. The lack of reliable data on the prevalence of
HPV and related cervical lesions hampers the establish-
ment of evidence-based intervention programmes. In
addition, a direct comparison with an age-matched con-
trol group is often difficult due to a lack of data, and the
use of different laboratory tests makes comparisons
among studies difficult. However, the major hurdle is
that many FSWs start sex work when they are younger
than the screening age recommended by the respective
national cervical cancer screening programmes, and
therefore, there often is no readily available control
group among younger age cohorts.
The main aim of this cross-sectional survey is to deter-
mine the prevalence of hrHPV and HPV genotype distri-
butions among FSWs in Antwerp. In addition, the OR
for hrHPV DNA positivity, HPV genotypes and cytology
compared to the general population are investigated.
Methods
The study was performed in accordance with the
Helsinki Declaration, procedures established by Belgian
law and the guidelines of ICH-GCP. Ethical approval
was obtained from the medical ethical board of Antwerp
University (Ref: B30020072416).
Setting and population
The Antwerp health house for prostitution (Ghapro) of-
fers sex workers free and anonymous screenings for
sexually transmitted infections (STIs) as well as advice
and education on sex work-related issues (http://
www.ghapro.be/en/index.html). This nested case-control
study was based on the results of cervical cytological
screenings and hrHPV testing of all FSWs visiting the
Ghapro clinic between June 2006 and June 2010. This
data was selected from the laboratory database of the
Laboratory for Clinical and Molecular Pathology (part
of National Reference Center for HPV), Antwerp,
Belgium. All samples were processed in this laboratory.
For women tested on multiple occasions during this
period, only the first screening results were included.
A control group was selected from the same laboratory
database (general female population). All FSWs were
matched 1:1 for age, testing date, and location (Antwerp
region). As with the FSWs, only the first set of results
during this testing period was taken into account for the
controls.
Pregnant women were not screened. Women with im-
munodeficiency conditions, such as HIV, and women
without a reported age or date of birth were excluded
from the study.
Laboratory analysis
Sample processing and cytological procedure
Cervical cells were collected using the Cervix-Brush®
Combi (Rovers, Oss, The Netherlands). After collection,
brush heads were transferred directly into alcohol-based
preservatives (BD SurePath™, BD Diagnostics – TriPath,
NC, USA). All vials were transported to the Laboratory
for Clinical and Molecular Pathology, Antwerp, Belgium.
Thin-layer slides were prepared with the robotic BD
PrepStain™ Slide Processor (BD Diagnostics–TriPath,
Burlington, NC, USA) [10]. Cytology screening was
performed with prior knowledge of HPV identically in
both groups as described earlier [11]. The cytological
results were reported according to the Bethesda system
2001 [12].
Type-specific HPV detection
DNA isolation from liquid-based cytology was per-
formed as previously described [13]. A clinically vali-
dated, real-time, quantitative PCR was used to amplify
18 HPV types: HPV 6E6, 11E6, 16E7, 18E7, 31E6, 33E6,
35E6, 39E7, 45E7, 51E7, 52E7, 53E6, 56E7, 58E7, 59E7,
66E6, 67 L1 and 68E7 [14]. For further analyses, HPV
genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
and 68 were used as the high-risk HPV (hrHPV) geno-
types. Real-time quantitative PCR for β-globin was al-
ways performed and was used as a proxy for the quality
of sampling. The amount of β-globin DNA (in nano-
grams) present in each sample was divided by the weight
of 1 genome equivalent (i.e., 6.6 picogram/cell) to obtain
the number of genome equivalents in the sample.
Statistics
Data analysis included descriptive statistics, cross-
tabulations, and graphical representations using SPSS,
version 22. Forest plots were created in Excel, version
2013. Odds Ratios (OR) of this nested case-control study
are calculated by conditional logistic regression using
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COXREG in SPSS. All statistical tests were conducted at
a 5 % significance level, and 95 % confidence intervals
were computed.
Results
A total of 2106 samples from FSWs between June 2006
and June 2010 were tested. Of these, 753 were excluded
because they were samples from FSWs who had already
been tested earlier in the study period. In addition, 3
FSWs were excluded due to HIV positivity, and 15 were
excluded because age was not available. The 1334 con-
trols were selected from 200,736 data sets from women
living in the Antwerp region. The analysis was
performed on samples from 1334 FSWs and 1334 age-
matched controls.
Socio-demographics
The average age of the FSWs was 29.10 years (range, 17
to 70 years). The number of FSWs in each age group is
shown in Fig. 1. For each FSW, a control of the same
age who was tested on average 0.88 days after the FSW
was identified (618 controls were tested on the same day
and 464 on the following day, and the maximum interval
between testing the FSW and the control was 7 days).
Nationality was known for 1,254 FSWs (94 %). The
majority (70 %, 877/1254) were European. Table 1 shows
the top ten countries of origin and the mean age of the
FSWs. Briefly, the top four countries of origin were
Belgium, Nigeria, Bulgaria, and Romania, with 344, 130,
123, and 105 FSWs, respectively, followed by the
Netherlands, no country reported, Thailand, the
Dominican Republic, Poland, and Albania, with 97, 80,
75, 38, 36, and 28 FSWs, respectively. Significant differ-
ences in the average age for different nationalities were
observed. The youngest FSWs were Romanian, Bulgarian
and Nigerian, with an average age of 23, 24, and 26 years,
respectively. Older FSWs originated from Belgium, the
Dominican Republic and Thailand, with an average age
of 32, 33, and 34 years, respectively. The controls were
randomly selected from women living in the same region
(Antwerp province). Data on nationality or origin was
not available for the controls.
hrHPV prevalence
The overall hrHPV prevalence for FSWs (41.7 %) was
significantly higher than for the control group (19.8 %)
(p <0.00001). The OR for hrHPV in FSWs compared to
the controls was 2.8 (95 % CI: 2.3–3.4). Figure 2 pro-
vides an overview of the different HPV genotypes among
FSWs and controls.
The most common hrHPV genotypes in all FSWs were
HPV-16 (12.1 %), HPV-31 (8.9 %) and HPV-52 (7.0 %).
The most common hrHPV genotypes in the controls were
HPV-16 (6.6 %), HPV-51 (4.5 %) and HPV-31 (4.0 %).
Both groups (FSW and controls) had mostly single
infections (59.3 and 65.2 %, respectively) and duo-
infections (24.8 and 20.5 %, respectively). Small percentages
of both groups (FSW and controls) had 3 or more hrHPV
infections (15.8 and 14.4 %, respectively). There was no sig-
nificant difference (p = 0.11) in the occurrence of multiple
infections (2 or more) between groups, with 40.6 % in the
FSW group and 34.8 % in the control group. Only FSWs
younger than 21 years of age had significantly more
multiple infections (2 or more) than did the controls, at
51.0 and 27.2 %, respectively (p = 0.04).
Demographic characteristics in relation to hrHPV
occurrence
Figure 1 compares the hrHPV prevalence by age in both
groups. Significant differences were observed in all age
groups and in particular in the age cohort under 21 years
(n = 149) (p < 0.05). In FSWs younger than 21 years old,
a prevalence of 64.4 % was observed with an OR of 10.3
(95 % CI: 5.0–21.2). The group between 36 and 40 years
of age showed a significantly higher hrHPV prevalence
Age
group
hrHPV
neg
hrHPV
pos
HPV
pos %
hrHPV
neg
hrHPV
pos
HPV
pos %
<21 127 22 14.8 53 96 64.4 10.3 5.0-21.2 <0.001
21-25 288 102 26.2 212 178 45.6 2.2 1.6-2.9 <0.001
26-30 264 77 22.6 212 129 37.8 2.1 1.5-2.9 <0.001
31-35 151 36 19.3 117 70 37.4 2.9 1.7-4.9 <0.001
36-40 115 8 6.5 85 38 30.9 5.3 2.4-11.9 <0.001
>40 125 19 13.2 99 45 31.3 2.7 1.5-4.9 0.001
All 1070 264 19.8 778 556 41.7 2.8 2.3-3.4 <0.001
Controls FSW
OR 95% CI p-value
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
OR
Fig. 1 Prevalence of hrHPV DNA in female sex workers (FSWs) compared to an age-matched control group in Antwerp, Belgium
Vorsters et al. BMC Public Health  (2016) 16:477 Page 3 of 8
among FSWs than controls, with an OR of 5.3 (95 % CI:
2.4–11.9).
Cervical lesions (cellular abnormalities)
Figure 3 and Table 2 show the cytological results for the
FSW and control groups. Cellular abnormalities were
observed in approximately one-third of FSWs (27.7 %),
which was significantly higher than in the controls
(11.6 %) (p <0.05). In addition, significantly more ASCUS
(atypical squamous cells of undetermined significance)
and LSIL (low-grade squamous intraepithelial lesions)
were diagnosed in FSWs than in controls, with ORs of 2.8
(95 % CI: 2.0–3.7) and 2.9 (95 % CI: 2.2–4.0), respectively.
In FSWs with AGC (atypical glandular cells) (n = 3),
ASC-H (atypical squamous cells cannot exclude high-
grade squamous intraepithelial lesions) (n = 6) or HSIL
(high-grade squamous intraepithelial) (n = 27) was de-
tected. In cases with LSIL and ASCUS, we found hrHPV
prevalences of 91 % and 83 %, respectively. The hrHPV
prevalence in FSWs with normal cytology was 26 %.
Looking at the different age groups in table 2, a signifi-
cant difference in the number of cellular abnormalities
between FSWs and controls was observed in all age
groups. Again, the difference was most pronounced in
the youngest age group, < 21 years (p <0.001).
Discussion
To our knowledge, this is the largest nested case-control
study (2 N = 2668) describing hrHPV genotyping in
FSWs [15]. Overall, the hrHPV prevalence was signifi-
cantly higher in FSWs (41.7 %) than in the general popu-
lation (19.8 %).
A 2013 literature review and analysis of the results of
35 HPV-prevalence studies in FSWs reported a median
overall prevalence of HPV infections in FSWs of 42.7 %,
with a range of 2.3 to 100 % [15]. This is comparable to
our results (41.7 %). A 2004 study in the Belgian region
of Ghent reported an HPV prevalence of 77 % in 93
FSWs [16]. However, the sample size was smaller, the
detection technique was different and the population
Table 1 Female sex workers top ten countries of origin and
mean age
Country Number of FSW Mean age in years
(5th-95th percentile)
Belgium 344 32 (20–48)
Nigeria 130 26 (21–32)
Bulgaria 123 24 (18–27)
Romania 105 23 (19–28)
Netherlands 97 30 (20–46)
no country reported 80 27 (18–45)
Thailand 75 34 (21–46)
Dominical Republic 38 33 (20–48)
Poland 36 28 (19–42)
Albania 28 29 (23–35)
Fig. 2 HPV genotype-specific prevalence in female sex workers (FSWs) compared to an age-matched control group in Antwerp, Belgium
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characteristics may not have been the same as in our
study. Also in 2004, a study in the Antwerp region com-
pared a group of FSWs (N = 61) with the general popula-
tion (N = 84) and found that the HPV prevalence in
FSWs was significantly higher (34.4 % in FSWs and
22.8 % in controls) [17].
In both groups (Fig. 2), the most common hrHPV
genotype was HPV-16, and it was significantly more
prevalent in the FSW (12.1 %) than in the control group
(6.6 %). The second and third most common hrHPV ge-
notypes in FSWs were HPV-31 (8.9 %) and HPV-52
(7.1 %). Although the overall prevalence of hrHPV in a
review of 35 studies looking at HPV in FSWs is higher
than in our results, we identified the same predominant
genotypes, including HPV 16 (38.9 %), HPV 31 (28.4 %)
and HPV52 (32.7 %) [15].
The decreasing prevalence of hrHPV with age that we
observed in the control group confirms what is found in
the literature [8, 18, 19]. It is clear that a young age also
contributes to a high hrHPV prevalence, and this was
equally valid for FSWs. A study in Mombasa reported
an HPV prevalence of 52.1 % in 17- to 24-year-old HIV-
negative FSWs, which is comparable to the 50.9 %
hrHPV prevalence we found in the under 25 years
cohort in this study [20].
In addition to frequent exposure to multiple sex part-
ners, we want to emphasize the frequent use of vaginal
douching in this group. This procedure is known to alter
the vaginal microbiome and to frequently cause bacterial
vaginosis (BV) [21]. Based on a meta-analysis of 12
studies, an association between BV and cervical HPV
infection has been reported [22]. Interestingly, it has
Fig. 3 Cytology in female sex workers (FSWs) compared to an age-matched control group in Antwerp, Belgium
Table 2 Cytological results of FSWs compared to age-matched controls according to different age groups
Age groups NILM ASC-US AGC LSIL ASC-H HSIL Total p-value*
<21 Controls 136 8 5 0 149 <0.001
FSWs 80 36 32 1 149
21–25 Controls 333 25 1 25 2 4 390 <0.001
FSWs 272 50 0 57 2 9 390
26–30 Controls 297 16 0 17 2 9 341 0.022
FSWs 275 34 1 24 1 6 341
31–35 Controls 166 7 0 8 4 2 187 <0.001
FSWs 134 21 2 22 3 5 187
36–40 Controls 115 6 2 0 123 <0.001
FSWs 92 17 11 3 123
>40 Controls 132 7 3 2 0 144 0.004
FSWs 112 15 0 14 3 144
Total Controls 1179 69 4 59 8 15 1334 <0.001
FSWs 965 173 3 160 6 27 1334
AGC atypical glandular cells, ASC-H atypical squamous cells cannot exclude high-grade squamous intraepithelial lesions, ASCUS atypical squamous cells of
undetermined significance, HSIL high-grade squamous intraepithelial lesions, LSIL low-grade squamous intraepithelial lesions
*: p-value is calculated using Chi Square based on cased of NILM, ASC-US and combined categories of AGC, LSIL, ASC-H and HSIL
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recently been shown that the conditions that prevent
BV (i.e., when the vaginal microbiota is dominated by
Lactobacillus gasseri) are associated with an increased
clearance of detectable HPV [23]. The often-deregulated
vaginal microbiota in FSWs may therefore also contribute
to the major differences we observed between FSWs
and the control group. Further studies are needed to
confirm this.
The need for tailored interventions: cervical screening
Most HPV studies in FSWs describe hrHPV prevalence,
but only a few papers also provide cytological or histo-
logical results. Two studies reporting on both cytology
and histology in FSWs found more cellular abnormal-
ities in FSWs than in the general population, which con-
firms our findings [16, 24]. In addition, we have reported
and confirmed significantly more HPV infections and
abnormal smear results in the youngest age cohort (17
to 21 years old). Recent recommendations from the
Belgian Health Care Knowledge Centre advise starting
cytology screening at the age of 25 with an interval of
3 years until age 30 and then performing HPV DNA
screening every 5 years [25]. However, after observing
the significant differences in hrHPV prevalence and ab-
normal cytology between the FSW and control groups, it
is clear that further research is needed to protect FSWs
from the consequences of HPV infections. In addition,
targeting FSWs is challenging as they tend to move
within and between countries, and an effective screening
follow-up may be difficult if the time interval between
two samplings is too long. These observations support
the need for further research on tailored screening
guidelines. Starting earlier, sampling more frequently
and referring FSWs for colposcopies sooner are all options
to be considered.
The need for tailored interventions: HPV vaccination
Regarding HPV vaccination, the current guidelines for
older women may need to be refined. It has been clearly
demonstrated that HPV vaccines are most effective when
administered before exposure to HPV because they have
no therapeutic effects and protect against HPV types not
yet acquired at the time of vaccination [26, 27]. For the
general population, it has been calculated that the vac-
cination of women up to age 30 may still be cost effect-
ive [28]. At later ages, the cost effectiveness decreases.
This is partly due to limited new infections in women over
age 30. However, the career of an FSW can last a lifetime
(the results presented here are taken from FSWs between
17 and 70 years old), and as frequent sexual contact with
‘non-vaccinated’ males from the general population may
be substantial, exposure to hrHPV continues. In addition,
we know that some women start sex work at a later age.
Indeed, in this study, we also report a significant
difference in hrHPV DNA positivity in 31- to 40-year-old
FSWs compared to the controls (p < 0.0001).
The health benefits of vaccination in this high-risk
group, which has significantly more HPV infections,
more cervical lesions and more exposure to non-
vaccinated males, may be substantially different than in
women from the general population. It seems obvious to
investigate, in line with other occupational health immu-
nisations, whether it would be beneficial to offer catch-
up vaccinations for this specific at risk population.
In Flanders, free vaccinations for one age-cohort of
girls between 10 and 13 years of age have been offered
since 2010 through a school vaccination programme. In
addition, a free catch-up vaccine is offered up to age 18.
In the first year of implementation (the 2010–2011
school year), 3 doses of the vaccine were administered to
83.5 % of the 11 year old girl population [29]. This
means that the majority of Flemish FSWs may soon have
received the HPV vaccination. However, such a preventa-
tive programme covers only part of the FSW population
because only 25 % of the FSWs in this study were Belgian.
In addition, lower vaccination coverage in Flanders was
linked to lower social class [30]. Therefore, the impact of
the national vaccination programme may be lower in this
high-risk group. This justifies additional research on the
potential benefits and feasibility of catch-up vaccinations
in the FSW population.
Strengths and limitations
To our knowledge, this is the largest study on HPV
genotyping in FSWs. The city of Antwerp has 510,000
inhabitants representing more than 160 different nation-
alities as well as a major port. This diversity is also
reflected in the population of FSWs visiting the health
house (http://www.ghapro.be/en/index.html), where 65
different nationalities are registered. We only included
FSWs who came for routine screening for cervical can-
cer and not on FSWs in general, although the test is
available if necessary. Furthermore, the selection of the
controls with perfect case control match for age and
testing date is a unique feature of this study. A bias
could have occurred only in the youngest age cohort be-
cause there are no standard screening guidelines for this
cohort, and we may have selected proportionally more
sexually active girls. In Belgium, a number of treating
physicians and gynaecologists do screen young girls
(<21 years) during consultations for oral contraceptive
prescriptions. In addition, many physicians screen young
girls after childbirth. In both cases, these women were
sexually active, and any selection bias would generate a
higher prevalence in the youngest control group and po-
tentially mask the specific impact of sex work at young
ages. A number of physicians and gynaecologists rou-
tinely take pap smears starting at the age of 21, and this
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should be a representative control group. These data
clearly confirm the previously reported increased hrHPV
prevalence and increased number of abnormal cervical
smears in this high-risk population.
Although we selected cases and controls that were
reported for the first time in the database, we cannot ex-
clude the possibility that both cases and controls were
previously tested by another laboratory or in their coun-
try of origin. However, in most countries, including
Belgium, no official screening programme is available for
young women, so we expect that this had a limited im-
pact on the reported prevalence. Another potential bias
in this study is the sampling. The samples from the con-
trol group contained significantly more human DNA
than did the FSW samples collected by Ghapro (data not
shown). It is not clear whether this is due to possible
differences in the level in the cervix from multiple wash-
ings, the application of creams, or other factors. How-
ever, the collected samples still contained enough
material to adequately detect an HPV infection. Even if
this influenced the presented results, it would have led
to an underestimation of HPV infection in FSWs, again
masking the impact of sex work on HPV prevalence and
abnormal cytology.
Conclusions
This study confirms that FSWs have an increased
hrHPV prevalence as well as an increased prevalence of
premalignant lesions. This effect is very pronounced in
the under 21 years group. To protect this higher-risk
population, specific prevention and control measures
may be appropriate, including adapted HPV screening
and vaccination programmes. Tailored prevention and
control interventions that take into account the multiple
occupational contacts of FSWs will also lead to a direct
benefit for the general population.
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